COAG
Hemab Therapeutics Holdings Inc. Common Stock (COAG)
Healthcare • NASDAQ • $46.67-5.07%
- Symbol
- COAG
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $46.67
- Daily Change
- -5.07%
- Market Cap
- $2.30B
- Trailing P/E
- N/A
- Forward P/E
- -19.37
- 52W High
- $55.42
- 52W Low
- $23.00
- Analyst Target
- $61.20
- Dividend Yield
- N/A
- Beta
- N/A
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachu…
Company websiteResearch COAG on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.